[1]Parkin DM.The global health burden of infection-associated cancers in the year 2002[J].Int J Cancer,2006,118(12):3030-3044 [2]Trimble C.L.，Frazer IH[J].Development of therapeutic HPV vaccines. Lancet Oncol,2009,10(10):975-980 [3]Munoz N, Bosch FX, de Sanjose S, et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer[J].N Engl J Med,2003,348(6):518-527 [4]zur Hausen H.Papillomaviruses and cancer: from basic studies to clinical application[J].Nat Rev Cancer,2002,2(5):342-350 [5]Crook T., Morgenstern J[J].P., Crawford L. et al. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. The EMBO Journal,1989,8(2):513-519 [6]Munger K, Howley PM.Human papillomavirus immortalization and transformation functions[J].Virus Res,2002,89(2):213-228 [7]Mahdavi A，Monk BJ.Vaccines against human papillomavirus and cervical cancer: promises and challenges[J].Oncologist,2005,10(7):528-538 [8]Hung CF, Ma B, Monie A., et al[J].Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin. Biol.Ther,2008,8(4):421-439 [9]Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al.Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice[J].Cancer Immunol Immunother,2007,56(7):997-1007 [10]Liao J.B., Publicover J[J]., Rose J.K.，et al. Single-Dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein._Clin. Vaccine Immunol,2008,15(5):817-824 [11]Riezebos-Brilman A, Regts J, Freyschmidt E-J, et al.Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7 transgenic mice[J].Gene Therapy,2005,12(18):1410-1414 [12]Sewell D.A.，Pan ZK, Paterson Y[J].Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine,2008,26(41):5315-5320 [13]Kenter GG., Welters M[J].J.P., Valentijn A.R.P.M., et al. Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. N Engl J Med,2009,361(19):1838-1847 [14]Karanam B, Gambhira R, Peng SW, et al.Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity[J].Vaccine,2009,27(7):1040-1049 [15]Chuang CM, Hoory T, Monie A, et al.Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells[J].Vaccine,2009,27(5):684-689 [16]Huang B, Mao CP, Peng SW, et al.RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency[J].Hum Gene Ther,2008,19(8):763-773 [17]Kim TW, Hung CF, Juang J, et al.Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death[J].Gene Ther,2004,11(3):336-342 [18]Kim JH, Kang TH, Noh KH et al.Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8+ T cell-mediated cell death[J].Immunology Letters,2009,122(1):58-67 [19]Kang TH, Lee JH, Bae HC, et al.Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments[J].Immunology Letters,2006,106(2):126-134 [20]Santin AD, Bellone S., Palmieri M[J]., et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol,2008,82(4):1968-1979 [21]Lin CT, Hung CF, Juang J，et al.Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles[J].Mol Ther,2003,8(4):559-566 [22]Kang TH, Lee JH, Song CK, et al.Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination[J].Cancer Res,2007,67(2):802-811